GURU.Markets stock price, segment price, and overall market index valuation
The company's share price IGC Pharma Inc.
IGC Pharma is a biopharmaceutical company developing cannabinoid-based drugs for the treatment of Alzheimer's disease. Its stock price is highly speculative and driven by news of clinical trials in this highly complex area of medicine.
Share prices of companies in the market segment - Narco farm
IGC Pharma is a pharmaceutical company developing cannabinoid-based drugs for the treatment of neurodegenerative diseases such as Alzheimer's. We have classified it as a "Narco-Pharma" company. The chart below shows how investors assess the medical potential of cannabis derivatives.
Broad Market Index - GURU.Markets
IGC Pharma is a biopharmaceutical company developing cannabinoid-based drugs for the treatment of neurodegenerative diseases such as Alzheimer's. As a component of the GURU.Markets index, it represents the medical marijuana sector. The chart below represents the entire market. See how this company's stock compares to the overall trend.
Change in the price of a company, segment, and market as a whole per day
IGC - Daily change in the company's share price IGC Pharma Inc.
For IGC Pharma, Inc., which is developing cannabinoid-based drugs for the treatment of Alzheimer's disease, daily volatility reflects sensitivity to clinical trial data. This metric is an important element in risk assessment.
Daily change in the price of a set of shares in a market segment - Narco farm
IGC Pharma, Inc. is a biotech company focused on cannabinoids. This chart highlights the sector's extreme volatility. Comparison with IGC, which focuses on Alzheimer's disease treatments, helps to assess it as a high-risk asset.
Daily change in the price of a broad market stock, index - GURU.Markets
IGC Pharma develops cannabinoid-based drugs for the treatment of Alzheimer's disease. The company operates at the intersection of two volatile sectors: biotech and cannabis. Its shares respond to scientific and regulatory news, adding unique dynamics to the market.
Dynamics of market capitalization of the company, segment and the market as a whole over 12 months
Annual dynamics of the company's market capitalization IGC Pharma Inc.
For IGC Pharma, Inc., the year-over-year performance is a story about developing cannabinoid-based drugs for the treatment of Alzheimer's disease. Its 12-month market cap is entirely dependent on clinical trial data. The success of its lead candidate could be a breakthrough in this highly complex field, but the risks remain extremely high.
Annual dynamics of market capitalization of the market segment - Narco farm
IGC Pharma, Inc. is a biotechnology company developing cannabinoid-based drugs for the treatment of Alzheimer's disease. Its stock price is entirely speculative and based on investor faith in its scientific hypotheses, which is typical for this high-risk field.
Annual dynamics of market capitalization of broad market stocks, index - GURU.Markets
IGC Pharma, a biotech company researching drugs to treat Alzheimer's disease, is one of the most speculative stories on the market. Its stock price is completely unrelated to the economy. Its chart reflects the hopes, risks, and shifts in investor sentiment surrounding its developments.
Dynamics of market capitalization of the company, segment and the market as a whole for the month
Monthly dynamics of the company's market capitalization IGC Pharma Inc.
IGC Pharma is developing cannabinoid-based drugs for the treatment of Alzheimer's disease. Its monthly dynamics depend entirely on the results of its clinical trials. Data for its lead drug are binary events, causing sharp fluctuations.
Monthly dynamics of market capitalization of the market segment - Narco farm
IGC Pharma is developing cannabinoid-based drugs for the treatment of diseases such as Alzheimer's. This sector lies at the intersection of biotech and the cannabis industry. The chart below reflects how investors assessed the scientific and commercial potential of medical cannabis, as well as the associated regulatory risks.
Monthly dynamics of market capitalization of broad market stocks, index - GURU.Markets
IGC Pharma is a pharmaceutical company developing cannabinoid-based treatments for, among other things, Alzheimer's disease. Its stock price reflects a combination of biotech risk and regulatory risks associated with cannabis. This is a highly speculative story.
Dynamics of market capitalization of the company, segment and the market as a whole for the week
Weekly dynamics of the company's market capitalization IGC Pharma Inc.
IGC Pharma is a pharmaceutical company developing cannabinoid-based drugs for the treatment of Alzheimer's disease. Its weekly stock price is highly volatile and speculative, heavily dependent on news about clinical trials and changes in cannabis legislation.
Weekly dynamics of market capitalization of the market segment - Narco farm
IGC Pharma is a pharmaceutical company developing cannabinoid-based drugs for the treatment of Alzheimer's disease. Its weekly stock price is highly volatile and speculative, heavily dependent on news about clinical trials and changes in cannabis legislation.
Weekly dynamics of market capitalization of stocks of the broad market, index - GURU.Markets
Shares of IGC Pharma, a company active in the cannabinoid space, live in a world of their own. Their performance is driven by news about legalization and research. A chart comparing the stock to the S&P 500 clearly demonstrates how the stock can rise or fall, completely ignoring the broader market.
Market capitalization of the company, segment and market as a whole
IGC - Market capitalization of the company IGC Pharma Inc.
IGC Pharma's market capitalization is a speculative story at the intersection of pharmaceuticals and cannabis. The company's price chart, which is developing cannabinoid-based drugs for the treatment of Alzheimer's disease, reflects all the risks and hopes associated with this field. Its volatility reflects the market's reaction to trial data and regulatory news.
IGC - Share of the company's market capitalization IGC Pharma Inc. within the market segment - Narco farm
IGC Pharma is a pharmaceutical company developing cannabinoid-based drugs for the treatment of Alzheimer's disease. Its market capitalization in its niche segment reflects the potential of its developments. The chart below shows high volatility associated with clinical trials and regulatory risks.
Market capitalization of the market segment - Narco farm
IGC Pharma is developing cannabinoid-based drugs to treat the symptoms of Alzheimer's disease. The chart below shows the overall market capitalization of the narcotic pharmaceuticals sector. It reflects both the scientific interest in medical cannabis and the high regulatory barriers in this field.
Market capitalization of all companies included in a broad market index - GURU.Markets
This illustrates the use of cannabinoids in medicine. IGC Pharma is developing cannabis-based drugs to treat the symptoms of Alzheimer's disease. Its volatile pipeline reflects both the scientific potential and the regulatory complexities and skepticism surrounding medical cannabis.
Book value capitalization of the company, segment and market as a whole
IGC - Book value capitalization of the company IGC Pharma Inc.
IGC Pharma's capital lies in its intellectual property for cannabinoid-based drugs for the treatment of Alzheimer's disease and other disorders. This represents unique scientific capital at the intersection of pharmaceuticals and cannabis. The chart below shows how the company manages its resources to conduct clinical trials of its unconventional drug candidates.
IGC - Share of the company's book capitalization IGC Pharma Inc. within the market segment - Narco farm
IGC Pharma is a pharmaceutical company developing cannabinoid-based drugs for the treatment of Alzheimer's disease. Its assets include laboratories and intellectual property. The chart shows a minimal share of physical assets, as it is an R&D company.
Market segment balance sheet capitalization - Narco farm
Cannabinoid-based pharmaceuticals, as the BCap_Ges chart shows, are science-intensive. IGC Pharma, which is developing drugs for Alzheimer's disease, is investing in clinical trials rather than building factories.
Book value of all companies included in the broad market index - GURU.Markets
IGC Pharma's assets are capital invested in clinical trials of cannabinoid-based drugs for the treatment of Alzheimer's disease. This book value provides the financial foundation that allows the company to explore how plant-based raw materials can become tangible medicine for the brain.
The ratio of market capitalization to book capitalization of a company, segment, and the market as a whole
Market capitalization to book capitalization ratio - IGC Pharma Inc.
IGC Pharma is conducting research into cannabinoids for the treatment of Alzheimer's disease. This is a highly speculative area. The company's book value represents the money spent on research. Its market capitalization represents a pure bet on success in one of the most complex areas of medicine. The MvsBCap chart will reflect the hype and news about its research progress.
Market to book capitalization ratio in a market segment - Narco farm
IGC Pharma is a pharmaceutical company developing cannabinoid-based drugs for the treatment of Alzheimer's disease. Its value is based on the potential of its developments. The chart shows how investors assess its chances of success in this complex field.
Market to book capitalization ratio for the market as a whole
IGC Pharma is developing cannabinoid-based drugs for the treatment of Alzheimer's disease. This is a highly risky but potentially highly profitable field. The company's market valuation reflects not its current assets, but rather its hopes for clinical success in treating one of humanity's most complex diseases.
Debts of the company, segment and market as a whole
IGC - Company debts IGC Pharma Inc.
IGC Pharma, a pharmaceutical company developing cannabinoid-based drugs for the treatment of Alzheimer's disease, is devoting all its capital to clinical trials. This is a high-risk area requiring significant long-term funding. This chart shows how the company manages its resources on the long and uncertain path to developing a new drug.
Market segment debts - Narco farm
IGC Pharma, Inc. is a pharmaceutical company developing cannabinoid-based drugs for the treatment of diseases such as Alzheimer's. Research in this area is fraught with regulatory and scientific challenges. This chart shows how the company funds its unique, yet risky, clinical trials.
Market debt in general
Debt to book value of the company, segment and market as a whole
The company's debt to book capitalization ratio IGC Pharma Inc.
IGC Pharma develops cannabinoid-based drugs for the treatment of diseases such as Alzheimer's. This chart reflects the financial risks associated with operating in a highly regulated and controversial field. High debt burden exacerbates the risks if clinical trials fail or the company faces legal challenges.
Market segment debt to market segment book capitalization - Narco farm
IGC Pharma develops cannabinoid-based drugs for the treatment of diseases such as Alzheimer's. The chart shows the sector's debt load. It helps assess how the company finances its research in a controversial but potentially promising area of medicine, and how its financial model reflects regulatory and clinical risks.
Debt to book value of all companies in the market
IGC Pharma, Inc. is focused on developing cannabinoid-based drugs for the treatment of diseases such as Alzheimer's. The presented debt-to-equity ratio is important for the biotech sector. It reflects the availability of risk capital necessary to conduct clinical trials in such a new and regulatory-complex field.
P/E of the company, segment and market as a whole
P/E - IGC Pharma Inc.
For IGC Pharma, Inc., a company researching cannabinoids for the treatment of Alzheimer's disease, this chart reflects investors' high-risk hopes. Its values reflect not current profits, but rather faith in a potential scientific breakthrough that could create a multi-billion dollar market, albeit with a high probability of failure.
P/E of the market segment - Narco farm
This chart shows the average price-to-earnings ratio for the pharmaceutical industry, where IGC Pharma is researching cannabinoids. This metric serves as a backdrop for assessing how the market weighs the enormous potential and high risks of IGC's Alzheimer's developments compared to traditional pharmaceuticals.
P/E of the market as a whole
IGC Pharma is a pharmaceutical company developing cannabinoid-based drugs for the treatment of serious illnesses such as Alzheimer's. This is a high-risk area at the intersection of biotech and the cannabis industry. This chart shows the market's risk appetite. It helps understand how the market evaluates the scientific validity of IGC's approach and what risks (clinical and regulatory) it factors into its pricing.
Future P/E of the company, segment and market as a whole
Future (projected) P/E of the company IGC Pharma Inc.
IGC Pharma is a pharmaceutical company developing cannabinoid-based drugs for the treatment of diseases such as Alzheimer's. This is a high-risk area. This chart shows how confident analysts are that clinical trials will prove the effectiveness of its approaches and lead to an approved drug.
%20P%2FE%20IGC%20Pharma%20Inc.&width=1500&height=450&colorIndex=35&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-IGC-Pharma-Inc.&v=1772655790621 "Chart of the company's future (projected) P/E IGC Pharma Inc.")
Future (projected) P/E of the market segment - Narco farm
IGC Pharma is developing cannabinoid-based drugs for the treatment of severe diseases such as Alzheimer's. This chart shows its future profitability expectations, allowing us to assess how the market perceives its research in this complex and still controversial area of medicine.
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20Narco%20farm&width=1500&height=450&colorIndex=36&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment-Narco-farm&v=1772655790651 "Future (projected) P/E graph of the market segment - Narco farm")
Future (projected) P/E of the market as a whole
IGC Pharma is a pharmaceutical company developing cannabinoid-based drugs for the treatment of diseases such as Alzheimer's. This is a high-risk field. This chart, showing investors' overall risk appetite, directly impacts IGC's ability to raise capital for its unconventional but potentially breakthrough research.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole&v=1772655790721 "Chart of the future (projected) P/E of the market as a whole")
Profit of the company, segment and market as a whole
Company profit IGC Pharma Inc.
IGC Pharma, Inc. is developing cannabinoid-based drugs for the treatment of diseases such as Alzheimer's. The company's profitability depends on the success of its clinical trials and regulatory changes. This chart shows how much money is being invested in research to turn a controversial plant into an approved drug.
Profit of companies in the market segment - Narco farm
IGC Pharma is a pharmaceutical company developing cannabinoid-based drugs for the treatment of diseases such as Alzheimer's. This is a risky but potentially breakthrough area of research. This chart illustrates the overall dynamics of the biotech sector, where companies working with unconventional molecules can discover entirely new therapeutic approaches.
Overall market profit
IGC Pharma is developing cannabinoid-based drugs for the treatment of Alzheimer's disease. This is a high-risk area. The overall market conditions, which this chart indirectly reflects, determine how willing investors are to invest in speculative biotech plays with potentially huge, but uncertain, returns.
Future (predicted) profit of the company, segment and market as a whole
Future (projected) profit of the company IGC Pharma Inc.
IGC Pharma is a pharmaceutical company focused on developing cannabinoid-based drugs for the treatment of neurodegenerative diseases such as Alzheimer's. This chart shows analysts' assessments of the likelihood of success of its clinical programs and the potential of this unconventional approach to medicine.
%20profit%20of%20the%20company%20IGC%20Pharma%20Inc.&width=1500&height=450&colorIndex=41&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-IGC-Pharma-Inc.&v=1772655790805 "Graph of future (projected) profit of the company IGC Pharma Inc.")
Future (predicted) profit of companies in the market segment - Narco farm
IGC Pharma, Inc. is a pharmaceutical company specializing in the development of cannabinoid-based drugs for the treatment of neurodegenerative diseases such as Alzheimer's. This chart shows profitability projections for the biotech sector. It reflects both the high potential and regulatory risks associated with medical cannabis research.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20Narco%20farm&width=1500&height=450&colorIndex=42&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment-Narco-farm&v=1772655790814 "Graph of future (predicted) profits of companies in a market segment - Narco farm")
Future (predicted) profit of the market as a whole
IGC Pharma is developing cannabinoid-based drugs for the treatment of diseases such as Alzheimer's. The company operates at the intersection of biotechnology and regulated industries. This chart, reflecting overall investor sentiment, impacts the availability of capital for research in controversial but potentially breakthrough areas of medicine.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole&v=1772655790829 "Chart of future (predicted) profits of the market as a whole")
P/S of the company, segment and market as a whole
P/S - IGC Pharma Inc.
IGC Pharma is developing cannabinoid-based drugs for the treatment of diseases such as Alzheimer's. This chart shows its estimated scientific potential. Its high price and minimal sales reflect expectations for the success of its unique approach in a complex medical field.
P/S market segment - Narco farm
IGC Pharma, Inc. is a pharmaceutical company specializing in the development of cannabinoid-based drugs for the treatment of Alzheimer's disease. This chart shows the average revenue estimate in the biotech sector. It helps understand the premium investors are placing on the potential of IGC's innovative approach to treating severe neurodegenerative diseases.
P/S of the market as a whole
IGC Pharma is a pharmaceutical company focused on developing cannabinoid-based drugs for the treatment of neurodegenerative diseases such as Alzheimer's. Their research straddles two hot topics. This chart provides a general revenue metric against which to judge how the market values cannabinoid-focused biotech.
Future P/S of the company, segment and market as a whole
Future (projected) P/S of the company IGC Pharma Inc.
IGC Pharma is a pharmaceutical company developing cannabinoid-based drugs for the treatment of Alzheimer's disease. This chart reflects investors' speculative expectations for its research. The valuation depends entirely on the success of clinical trials and potential approval of its innovative approach to treating neurodegenerative diseases.
%20P%2FS%20IGC%20Pharma%20Inc.&width=1500&height=450&colorIndex=47&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-IGC-Pharma-Inc.&v=1772655790889 "The graph of the company's future (projected) P/S IGC Pharma Inc.")
Future (projected) P/S of the market segment - Narco farm
IGC Pharma is a pharmaceutical company developing cannabinoid-based drugs for the treatment of diseases such as Alzheimer's. This is a high-risk but potentially disruptive segment. This chart shows how the market views its research compared to the neuroscience-focused biotech sector.
%20P%2FS%20market%20segment%20graph%20-%20Narco%20farm&width=1500&height=450&colorIndex=48&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph-Narco-farm&v=1772655790899 "Future (projected) P/S market segment graph - Narco farm")
Future (projected) P/S of the market as a whole
IGC Pharma specializes in developing cannabinoid-based drugs for the treatment of diseases such as Alzheimer's. This chart, reflecting investor appetite for risk and innovative approaches in medicine, is important for IGC. Market optimism allows such companies to more easily attract funding for research in controversial but potentially breakthrough areas.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole&v=1772655790916 "Chart of the future (projected) P/S of the market as a whole")
Sales of the company, segment and market as a whole
Company sales IGC Pharma Inc.
IGC Pharma is a pharmaceutical company developing cannabinoid-based drugs for the treatment of diseases such as Alzheimer's. This chart shows financial flows, which may include revenue from branded product sales or funding for clinical trials. It demonstrates progress in monetizing research in this controversial but promising field.
Sales of companies in the market segment - Narco farm
IGC Pharma, Inc. is a pharmaceutical company specializing in the development of cannabinoid-based therapies for the treatment of severe diseases, such as Alzheimer's disease. Its activities are segmented into various drug development programs. This chart depicts the financial flows associated with one of its key research areas.
Overall market sales
IGC Pharma, Inc. is a pharmaceutical company developing cannabinoid-based treatments for conditions such as Alzheimer's disease. The company operates at the intersection of biotechnology and cannabis legalization. Its success depends on clinical trial results and changes in the regulatory environment, which exemplifies the creation of a new medical market.
Future sales volume of the company, segment and market as a whole
Future (projected) sales of the company IGC Pharma Inc.
IGC Pharma is a pharmaceutical company specializing in the development of cannabinoid-based drugs for the treatment of neurodegenerative diseases such as Alzheimer's disease. Its future sales forecast is based on expectations for the success of its clinical trials and potential approval of its unique therapeutic approaches.
%20sales%20of%20the%20company%20IGC%20Pharma%20Inc.&width=1500&height=450&colorIndex=53&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-IGC-Pharma-Inc.&v=1772655791324 "Schedule of future (projected) sales of the company IGC Pharma Inc.")
Future (projected) sales of companies in the market segment - Narco farm
IGC Pharma, Inc. is a pharmaceutical company developing cannabinoid-based drugs for the treatment of Alzheimer's disease. This chart reflects expectations for the narcotic pharmaceuticals sector. It helps understand the potential analysts predict for medical cannabis for the treatment of neurodegenerative diseases.
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20Narco%20farm&width=1500&height=450&colorIndex=54&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment-Narco-farm&v=1772655791382 "Schedule of future (projected) sales of companies in the market segment - Narco farm")
Future (projected) sales of the market as a whole
IGC Pharma is developing cannabinoid-based drugs for the treatment of Alzheimer's disease. Its success depends on clinical trial results and regulatory approvals. This chart of overall sales forecasts reflects market sentiment, which influences funding for such innovative but risky research.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole&v=1772655791421 "Schedule of future (predicted) sales of the market as a whole")
Marginality of the company, segment and market as a whole
Company marginality IGC Pharma Inc.
IGC Pharma, Inc. is a pharmaceutical company developing cannabinoid-based drugs for the treatment of diseases such as Alzheimer's. This chart reflects its financial performance at the clinical trial stage, where high R&D expenditures are an investment in the development of innovative drugs in this controversial but promising field.
Market segment marginality - Narco farm
IGC Pharma is developing cannabinoid-based drugs to treat the symptoms of Alzheimer's disease. Effectiveness in this new and highly regulated field depends on successful clinical trials and the ability to navigate complex regulations. The chart below compares the company's operating model to other biotech companies.
Market marginality as a whole
IGC Pharma, Inc. is a pharmaceutical company developing cannabinoid-based drugs for the treatment of diseases such as Alzheimer's. The company operates at the intersection of biotechnology and cannabis legalization. This chart shows overall profitability, but for IGC, success depends on clinical trial results and changes in the regulatory environment.
Employees in the company, segment and market as a whole
Number of employees in the company IGC Pharma Inc.
IGC Pharma is exploring the use of cannabinoids to treat complex diseases like Alzheimer's. This graph shows a small team of scientists working at the intersection of pharmaceuticals and the cannabis industry. The team's size reflects the early, exploratory stage of this risky but potentially breakthrough field.
Share of the company's employees IGC Pharma Inc. within the market segment - Narco farm
IGC Pharma is focused on developing cannabinoid-based drugs for the treatment of conditions such as Alzheimer's disease. This controversial but promising field requires a robust scientific team. This chart shows its human capital investment in research into the therapeutic potential of cannabis.
Number of employees in the market segment - Narco farm
IGC Pharma specializes in developing cannabinoid-based drugs for the treatment of diseases such as Alzheimer's. This chart shows employment in the pharmaceutical sector. The growing number of scientists researching medical cannabis indicates legalization and scientific recognition of its therapeutic potential, creating a market for IGC's developments.
Number of employees in the market as a whole
IGC Pharma is developing cannabinoid-based drugs for the treatment of Alzheimer's disease. Its future depends on the results of clinical trials and regulatory approvals. This chart shows overall activity, but for IGC, one successful research report could change everything, attracting significant investment.
Market capitalization per employee (in thousands of dollars) of the company, segment, and market as a whole
Market capitalization per employee (in thousands of dollars) of the company IGC Pharma Inc. (IGC)
IGC Pharma, Inc. (formerly India Globalization Capital) is developing cannabinoid-based drugs for the treatment of Alzheimer's disease. This chart likely shows a high market capitalization per employee. The market is evaluating the potential for solving one of the most complex medical problems, which is intellectual capital.
%20of%20the%20company%20IGC%20Pharma%20Inc.%20(IGC)&width=1500&height=450&colorIndex=63&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-IGC-Pharma-Inc.-IGC&v=1772655791565 "Chart of market capitalization per employee (in thousands of dollars) of the company IGC Pharma Inc. (IGC)")
Market capitalization per employee (in thousands of dollars) in the market segment - Narco farm
IGC Pharma, Inc. focuses on developing cannabinoid-based drugs for the treatment of diseases such as Alzheimer's. In niche pharmaceuticals, this metric reflects investors' assessment of the company's scientific potential and the uniqueness of its approach. It indicates how valuable their research is perceived to be per scientist.
%20by%20market%20segment%20-%20Narco%20farm&width=1500&height=450&colorIndex=64&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment-Narco-farm&v=1772655791609 "Market capitalization per employee (in thousands of dollars) by market segment - Narco farm")
Market capitalization per employee (in thousands of dollars) for the overall market
IGC Pharma, Inc. is a pharmaceutical company developing cannabinoid-based drugs for the treatment of Alzheimer's disease. This is a complex and socially significant area of research. The chart shows the market's speculative assessment of the research team's potential to find new treatments.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market&v=1772655791654 "Market capitalization per employee (in thousands of dollars) for the overall market")
Profit per employee (in thousands of dollars) for the company, segment, and market as a whole
Profit per employee (in thousands of dollars) of the company IGC Pharma Inc. (IGC)
IGC Pharma (formerly IGC) is a biopharmaceutical company specializing in developing cannabinoid-based drugs for the treatment of Alzheimer's disease. This is a high-risk R&D area. This graph (negative) shows how much capital the company is investing in each scientist and physician to conduct clinical trials to prove the effectiveness of its dementia treatments.
%20Chart%20IGC%20Pharma%20Inc.%20(IGC)&width=1500&height=450&colorIndex=66&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-IGC-Pharma-Inc.-IGC&v=1772655791702 "Company Profit Per Employee (in thousands of dollars) Chart IGC Pharma Inc. (IGC)")
Profit per employee (in thousands of dollars) in the market segment - Narco farm
IGC Pharma develops cannabinoid-based drugs for the treatment of diseases such as Alzheimer's. In this highly specialized pharmaceutical niche, the scientific team plays a key role. This chart shows how financially productive their R&D is compared to other biopharmaceutical companies.
%20in%20the%20market%20segment%20-%20Narco%20farm&width=1500&height=450&colorIndex=67&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment-Narco-farm&v=1772655791781 "Chart of profit per employee (in thousands of dollars) in the market segment - Narco farm")
Profit per employee (in thousands of dollars) for the market as a whole
IGC Pharma (IGC) is a pharmaceutical company developing drugs, including cannabinoid-based ones, for the treatment of, for example, Alzheimer's disease. It is a clinical-stage R&D company. Negative profit per employee is the norm. The chart shows the "cost" of the team of scientists working on these specific drugs.
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole&v=1772655791787 "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Sales to employees of the company, segment and market as a whole
Sales per company employee IGC Pharma Inc. (IGC)
IGC Pharma specializes in developing cannabinoid-based drugs for the treatment of neurodegenerative diseases. While still in the clinical stage, its revenue may be minimal. This timeline will ultimately determine whether the company will be able to commercialize its developments in this controversial but promising field.
&width=1500&height=450&colorIndex=69&filename=GURU_Markets_-_Sales-chart-per-company-employee-IGC-Pharma-Inc.-IGC&v=1772655791877 "Sales chart per company employee IGC Pharma Inc. (IGC)")
Sales per employee in the market segment - Narco farm
IGC Pharma specializes in developing cannabinoid-based drugs for the treatment of severe diseases, such as Alzheimer's. This chart compares IGC's revenue per employee to the industry average. For an R&D company, this reflects how productive their research is, possibly thanks to partnerships.
Sales per employee for the market as a whole
IGC Pharma (IGC) is a pharmaceutical company focused on developing cannabinoid-based (marijuana) drugs for the treatment of Alzheimer's disease. This is a clinical-stage R&D company. The company has no commercial sales revenue. This graph will reflect $0, as all employees (scientists) are focused on clinical trials.
Short shares by company, segment and market as a whole
Shares shorted by company IGC Pharma Inc. (IGC)
IGC Pharma (IGC) is a pharmaceutical company focused on developing cannabinoid-based drugs for the treatment of Alzheimer's disease. The combination of "cannabis" and "Alzheimer's" is a double red flag for skeptics. This chart shows the number of investors who consider this idea pseudoscientific speculation.
&width=1500&height=450&colorIndex=72&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-IGC-Pharma-Inc.-IGC&v=1772655792104 "Short Shares Chart for the Company IGC Pharma Inc. (IGC)")
Shares shorted by market segment - Narco farm
IGC Pharma is a pharmaceutical company specializing in developing cannabinoid-based drugs for the treatment of Alzheimer's disease. This chart shows the odds against the cannabis pharma sector. It reflects investor skepticism regarding the clinical data and regulatory hurdles for marijuana-based drugs.
Shares shorted by the overall market
IGC Pharma is trying to use cannabinoids to treat Alzheimer's disease. It's the intersection of biotech and drug pharma, carrying dual risks. This chart illustrates the overall market pessimism. When investors are afraid, they flee speculative ventures, and IGC is a combination of scientific risk and regulatory uncertainty.
RSI 14 indicator for a company, segment, and market as a whole
The company's RSI 14 indicator IGC Pharma Inc. (IGC)
IGC Pharma, Inc. is a biotech company developing cannabinoid-based drugs to treat the symptoms of Alzheimer's disease. This industry is highly speculative. This oscillator measures the hype surrounding legalization and trials, showing overbought peaks (above 70) and deep oversold troughs (below 30).
&width=1500&height=450&colorIndex=75&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-IGC-Pharma-Inc.-IGC&v=1772655792338 "RSI 14 indicator chart for the company's stock IGC Pharma Inc. (IGC)")
RSI 14 Market Segment - Narco farm
IGC Pharma is a biopharmaceutical company at the intersection of medicine and cannabis. It develops cannabinoid-based drugs for the treatment of severe neurological conditions such as Alzheimer's disease. This chart shows the overall "temperature" of the entire speculative "pharma-cannabis" sector. It clearly demonstrates when the entire industry is overheated by expectations or oversold by news.
RSI 14 for the overall market
IGC Pharma (IGC) is pure speculation, as reflected in this chart. During periods of market euphoria, investors are willing to "buy the dream" and invest in the "future" (pharma/cannabis). During moments of panic (and in the absence of legalization), investors flee unprofitable "concepts," and these stocks are the first to be sold off.
Analyst consensus forecast for the company's share price, the segment, and the market as a whole
Analyst consensus stock price forecast IGC (IGC Pharma Inc.)
IGC Pharma is a pharmaceutical company developing cannabinoid-based drugs for the treatment of Alzheimer's disease symptoms (e.g., agitation). This chart shows the average target price. Analysts' forecasts are based on clinical data (e.g., for IGC-AD1) and regulatory risks.
&width=1500&height=450&colorIndex=78&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-IGC-IGC-Pharma-Inc.&v=1772655792413 "A chart showing analyst consensus forecasts for the expected stock price. IGC (IGC Pharma Inc.)")
The difference between the consensus estimate and the actual stock price IGC (IGC Pharma Inc.)
IGC Pharma is a biopharmaceutical company conducting clinical trials of cannabinoid-based (marijuana) drugs for the treatment of Alzheimer's disease. This chart shows how the current share price differs from the "fair" value predicted by analysts. It reflects their view on this unconventional R&D.
&width=1500&height=450&colorIndex=79&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-IGC-IGC-Pharma-Inc.&v=1772655792502 "A chart showing the difference between the consensus forecast and the actual stock price. IGC (IGC Pharma Inc.)")
Analyst consensus forecast for stock prices by market segment - Narco farm
IGC Pharma is a biotech company attempting to prove in clinical trials (FDA) that cannabinoids (marijuana) can treat the symptoms of Alzheimer's disease. This chart reflects general expectations for the "drug farm" sector. It shows whether experts believe in "medical" cannabis.
Analysts' consensus forecast for the overall market share price
IGC Pharma is a biotech company developing cannabinoid-based (marijuana-derived) drugs to treat agitation in Alzheimer's patients. This chart shows overall risk appetite. For IGC, which operates at the intersection of biotech and the speculative cannabis sector, overall market optimism (risk appetite) is critical for funding.
AKIMA index of the company, segment and market as a whole
AKiMA Company Index IGC Pharma Inc.
IGC Pharma is a cannabis biotech. They're trying to domesticate cannabis by developing cannabinoid-based drugs to treat the symptoms of Alzheimer's disease (agitation, dementia). This chart is a summary indicator of their double bet. It reflects their (loss-making) R&D pipeline and their (speculative) herbal supplement brand.
AKIMA Market Segment Index - Narco farm
IGC Pharma (IGC) is a biopharmaceutical company developing cannabinoid-based (cannabis) treatments for neurodegenerative diseases, particularly the symptoms of Alzheimer's dementia. The chart shows the average index for the segment, helping investors assess how IGC's risks and potential in this niche compare to the pharmaceutical industry average.
The AKIM Index for the overall market
IGC Pharma is a biotech company researching cannabinoids for the treatment of Alzheimer's and other diseases. This chart, which reflects the market average, provides a macro backdrop. It helps assess how this speculative story, combining cannabis and pharmaceuticals, compares to overall economic trends.
